Physician profile
Tanda N Lane
NPI 1891824108
$5,785.30
in general payments reported to CMS, 2019-2025
24 companies · $1,760 in 2025
The $1,760 reported for 2025 was more than what a typical Procedural Dermatology provider received nationally (typical 2025 total: $599).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $94.27 · 2020: $53.39 · 2021: $395 · 2022: $890 · 2023: $1,127 · 2024: $1,466 · 2025: $1,760.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,273 · Education: $79.99.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,272.72 |
| Education | $79.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,560.06 | 2019-2025 | |
| Regeneron Healthcare Solutions, INC. | $885.35 | 2021-2025 | Dupixent, Libtayo |
| Genzyme Corporation | $636.21 | 2021-2025 | |
| Ucb, INC. | $363.15 | 2022-2025 | Bimzelx, Cimzia |
| Leo Pharma INC. | $361.32 | 2022-2025 | Adbry, Anzupgo |
| E.R. Squibb & Sons, L.L.C. | $323.38 | 2022-2025 | Sotyktu |
| Galderma Laboratories, L.P. | $286.49 | 2019-2025 | Nemluvio, Dysport |
| Dermavant Sciences, INC. | $277.15 | 2022-2024 | Vtama |
| Arcutis Biotherapeutics, INC. | $160.38 | 2023-2024 | Zoryve |
| Allergan, INC. | $119.59 | 2019-2022 | |
| Sun Pharmaceutical Industries INC. | $117.11 | 2021-2025 | Odomzo |
| Janssen Biotech, INC. | $100.42 | 2020-2025 | Tremfya |
| Pfizer INC. | $99.89 | 2022-2025 | |
| Amgen INC. | $84.49 | 2019-2024 | Otezla |
| Sanofi-Aventis U.S. LLC | $79.99 | 2025 |
Show all 24 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Helsinn Therapeutics (U.S.), INC. | $77.12 | 2021-2025 | Valchlor |
| Boehringer Ingelheim Pharmaceuticals, INC. | $62.85 | 2023-2025 | Spevigo |
| Organon LLC | $43.04 | 2025 | Vtama |
| Kerecis Limited | $38.64 | 2025 | Kerecis Surgiclose, Kerecis Graftguide |
| Novartis Pharmaceuticals Corporation | $29.29 | 2025 | |
| Incyte Corporation | $24.39 | 2024 | Opzelura |
| Mayne Pharma Commercial LLC | $21.59 | 2025 | |
| Kyowa Kirin, INC. | $16.96 | 2025 | |
| Genentech USA, INC. | $16.44 | 2024 | Erivedge |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Tanda Lane listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.